Introducing @AdMachineAI. Manually prompting one image at a time is a waste of life. So I built this. One product photo. Endless 4k ad variations. Automatically. No waiting around. Just world class ad campaigns fast. Early access is live now. 👇🏼

Strongly held belief: The best audience? One you own, hands down. Why newsletters are making a comeback: 1. Your message isn't lost in the void but delivered directly to your reader's inbox. 2. You escape the algorithms and centralized social networks. 3. Your newsletter following is exponentially more valuable. Is it hard? Absolutely. But, in the end, it's your audience, your rules.

Elon Musk walking into Jeff Bezos’s home:

Now I have to actually review my work. Gross.

Be kind, warm, and generous today, my friends! 🤘🏼

Wow. 🤯

Insane take from Fable 5

Prompt: “Realistic Deadpool sitting in a meditative pose on a cloud focus on his eyes, incredible detail --ar 4:5 --s 750 --v 6.0 --style raw” Image generated with Midjourney & upscaled with @Magnific_AI.

Big brain energy here lol

It may take a while, but good humans always come out on top. 👏

Just a couple of goofballs living the dream. 📸 : @aleclizanetz instagr.am/p/CZepuG9rVM2/

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

This is a super exciting release - Claude Fable 5 is the same underlying model as Mythos but with added safeguards. The benchmarks are great and it's SOTA on everything by a margin but I'll add that *qualitatively* also, this is a major-version-bump-deserving step change forward (imo of the same order as Claude 4.5 was in November), peaking especially for long problem-solving sessions on very difficult problems. You can give it a lot more ambitious tasks than what you're used to, the model "gets it" and it will just go, and it's never felt this tempting to stop looking at the code at all (but don't do this in prod!). The model still has quirks that people will run into and the safeguards are configured to be a little too trigger happy for launch, which can hopefully be tuned over time. I feel a lot of things changing as working software increasingly comes out on a tap. The Jevon's paradox kicks in and I feel my own demand for software growing substantially. You can ask for anything - explainers, visualizers, dashboards, bespoke single-use apps (e.g. a full wandb that is hyper-specific just for your project), you can 10X your test suite, auto-optimize code, run giant research projects with custom HTML for the results, anything! "Free your mind" (Matrix ref). Really looking forward to all the things people build!

Claude Fable 5 changed how we work on the Claude Code team day to day. We used to verify that Claude did the work right. Now we verify that it's doing the right work. Here’s the 3 biggest changes:

BREAKING: Anthropic just dropped Claude Fable 5—this is Mythos, made safe for public release. It is the best coding model in the world. We've been testing it internally @every for the last week or so across coding, writing, marketing, editing, and more—here's our vibe check: - It broke our benchmarks. Fable scored a 91/100 on our Senior Engineer benchmark—this is human senior engineer level. The previous high score was Opus 4.8 at 63. GPT-5.5 is a 62. - It's a one-shot wonder. You can set it and forget for hours or overnight on huge coding tasks, and come back to completed work. It cleared entire production bug backlogs, built a playable 3D, and even made a 2-minute animated film—all one-shot. - Taste and attention to detail. In coding and knowledge work tasks, it has much better taste and attention to detail than we've ever seen. It gets subtle things right, adds little features you might not have thought of, and generally understands the assignment in ways that surprised us. - Great use of context. We set it loose analyzing customer feedback surveys and our website data and it came back with a crisp, clean report that identified a. our biggest problem and b. a concrete testable solution—and then we sent it off to build that. - It's best for power users. If you're already used to orchestrating multiple agents in your work, this model can do things that you've never seen before. If you're a knowledge worker or vibe coder with a more basic setup, you're not going to notice a huge difference—in fact, it probably isn't the right model for you. - It's very slow, token-hungry. Using this thing for regular knowledge work is like squashing an ant with a rocket launcher. It also routinely uses 500k to 1M tokens on tasks. That's why it's best for your heaviest jobs—but not as good for tasks like collaborative writing. - It's expensive. It's about twice as expensive as Opus, and it's also incredibly token hungry—so expect it to be something you'll use sparingly unless your company pays for it. Overall, I think of it like a warp drive for coding: It can get you across the galaxy in a few hours, when it used to take months or years. But it's not appropriate for getting around town—you need something faster, cheaper, and more maneuverable. The ceiling is extraordinarily high on this model though. Even our most advanced testers like @kieranklaassen felt like they were only scratching the surface of it. Want our full vibe check with all of our testing and benchmarks? Read it on @every: every.to/vibe-check/anthropi…

Introducing Claude Fable 5: a Mythos-class model that we’ve made safe for general use. Its capabilities exceed those of any model we’ve ever made generally available.

are we getting mythos today?!

👀 👀 👀

Friendly reminder: You have to act. You have to be willing to fail.

Roberto is the best in the game. Killer work, as always! 👏🏼